Patents Examined by Ilia I Ouspenski
  • Therapeutic use of inhibitors of t cell activation or stimulation
    Patent number: 11344605
    Abstract: The present invention relates to the use of inhibitors of T cell costimulation and/or activation and/or function in the treatment and/or prevention of cardiac pathologies, in particular heart failure diseases, and/or of related symptoms.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: May 31, 2022
    Assignee: Humanitas Mirasole S.p.A.
    Inventors: Marinos Kallikourdis, Gianluigi Condorelli
  • Anti-PD-1 antibodies and methods of use thereof
    Patent number: 11345755
    Abstract: The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: May 31, 2022
    Assignees: Agenus Inc., Ludwig Institute for Cancer Research Ltd., Memorial Sloan-Kettering Cancer Center
    Inventors: Marc Van Dijk, Cornelia Anne Mundt, Gerd Ritter, Jedd David Wolchok, Taha Merghoub, Roberta Zappasodi, Rikke Bæk Holmgaard, David Schaer, David Adam Savitsky, Nicholas Stuart Wilson
  • Anti-PD-1 antibodies and methods of use thereof
    Patent number: 11338035
    Abstract: The present invention provides antagonizing antibodies that bind to programmed cell death protein 1 (PD-1) and methods of using same. The anti-PD-1 antibodies can be used therapeutically alone or in combination with other therapeutics to treat cancer and other diseases.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: May 24, 2022
    Assignee: RINAT NEUROSCIENCE CORP.
    Inventors: Yasmina Noubia Abdiche, Helen Kim Cho, Wei-Hsien Ho, Karin Ute Jooss, Arvind Rajpal, Sawsan Youssef
  • Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
    Patent number: 11331347
    Abstract: The present invention provides a combined chimeric antigen receptor targeting CD19 and CD20 and application thereof. Specifically, the present invention provides a combined chimeric antigen receptor targeting CD19 and CD20, which comprises a scFv targeting CD19 and CD20, a hinge region, a transmembrane region, and an intracellular signaling domain. The present invention provides a nucleic acid molecule encoding the chimeric antigen receptor and a corresponding expression vector, a CAR-T cell, and applications thereof. The experimental results show that the chimeric antigen receptor provided by the present invention shows extremely high killing ability against tumor cells. The chimeric antigen receptor of the present invention targets CD19 and/or CD20 positive cells and can be used to treat CD19 and/or CD20 positive B-cell lymphoma, leukemia and other diseases.
    Type: Grant
    Filed: September 15, 2021
    Date of Patent: May 17, 2022
    Assignee: CELLULAR BIOMEDICINE GROUP HK LIMITED
    Inventors: Yihong Yao, Yanfeng Li, Yutian Wei, Shigui Zhu, Xin Yao, Jiaqi Huang
  • Determinants of cancer response to immunotherapy
    Patent number: 11332530
    Abstract: Molecular determinants of cancer response to immunotherapy are described, as are systems and tools for identifying and/or characterizing cancers likely to respond to immunotherapy.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: May 17, 2022
    Assignee: MEMORIAL SLOAN KETTERING CANCER CENTER
    Inventors: Timothy A. Chan, Nadeem Riaz
  • B7-H4 antibodies and methods of use thereof
    Patent number: 11306144
    Abstract: The present disclosure provides antibodies and antigen-binding fragments thereof that specifically bind to human B7-H4 (and optionally cynomolgus monkey, mouse, and/or rat B7-H4) and compositions comprising such antibodies or antigen-binding fragments thereof. In a specific aspect, the antibodies or antigen-binding fragments thereof that specifically bind to human B7-H4 increase T cell proliferation, increase interferon-gamma production, and/or deplete B7-H4 expressing cells via ADCC activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering an antibody or antigen-binding fragment thereof that specifically binds to human B7-H4.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: April 19, 2022
    Assignee: FIVE PRIME THERAPEUTICS, INC.
    Inventors: Charles Kaplan, Derrick Houser, Luis Borges, Gloria Brattich, David Bellovin, Felicia Kemp, Majid Ghoddusi, Nels P. Nielson, Kathy Miller, Maike Schmidt
  • Anti-PD-1 nano-antibody and application thereof
    Patent number: 11292841
    Abstract: An anti-PD-1 nano-antibody capable of blocking a binding interaction between PD-1 and a ligand thereof, PD-L1. Disclosed are the nano-antibody, a nucleotide sequence encoding the nano-antibody, a corresponding expression vector, a host cell expressing the nano-antibody, and a method of producing the nano-antibody. Also disclosed is a humanized PD-1 nano-antibody sequence. The humanized nano-antibody can block the binding interaction between PD-1 and the ligand thereof, PD-L1 while still retaining a high affinity.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: April 5, 2022
    Assignee: ZHEJIANG TERUISI PHARMACEUTICAL INC.
    Inventors: Youling Wu, Yujie Zhang, Xiaolin Chen, Binbin Shen, Xiaoning Shen
  • Dual cytokine fusion proteins comprising IL-10
    Patent number: 11292822
    Abstract: The application relates to a dual cytokine fusion protein composition, pharmaceutical composition, and/or formulation thereof comprising IL-10 or IL-10 variant molecules fused to a single chain variable fragment scaffolding system and a second cytokine, where the second cytokine is linked in the hinge region of the scFv. The application also relates to methods of using the dual cytokine fusion protein composition for treating cancer, inflammatory diseases or disorders, and immune and immune mediated diseases or disorders.
    Type: Grant
    Filed: March 11, 2021
    Date of Patent: April 5, 2022
    Assignee: DEKA BIOSCIENCES, INC.
    Inventor: John Mumm
  • CTLA4 fusion proteins for the treatment of diabetes
    Patent number: 11286303
    Abstract: A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus autoimmunity by administering an effective amount of a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule is provided herewith. The CTLA4 molecule may be a fusion protein of a CTLA4 extracellular region and an immunoglobulin, such as abatacept.
    Type: Grant
    Filed: March 18, 2019
    Date of Patent: March 29, 2022
    Assignee: Phaim Pharma Ltd
    Inventor: Tihamer Orban
  • Therapeutic and diagnostic methods for cancer
    Patent number: 11279767
    Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).
    Type: Grant
    Filed: August 28, 2018
    Date of Patent: March 22, 2022
    Assignees: Genentech, Inc., Foundation Medicine, Inc.
    Inventors: Richard Bourgon, David Fabrizio, Gregg Fine, Garrett M. Frampton, Priti Hegde, Sanjeev Mariathasan, Philip J. Stephens, James Xin Sun, Roman Yelensky
  • Dosing regimen of avelumab for the treatment of cancer
    Patent number: 11274154
    Abstract: The present invention relates to dosing regimen of avelumab for the treatment of cancer. In particular, the invention relates to improved dosing regimen of avelumab for the treatment of cancer.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: March 15, 2022
    Assignees: PFIZER INC., MERCK PATENT GMBH
    Inventors: Glen Ian Andrews, Carlo Leonel Bello, Satjit Singh Brar, Shaonan Wang, Pascal Girard
  • Anti-CTLA-4 antibodies and methods of use thereof
    Patent number: 11267889
    Abstract: The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: March 8, 2022
    Assignees: Agenus Inc., Ludwig Institute for Cancer Research Ltd., Memorial Sloan-Kettering Cancer Center
    Inventors: Marc Van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, David Adam Savitsky, Nicholas Stuart Wilson
  • CD80 and CD86 binding protein compositions and uses thereof
    Patent number: 11261233
    Abstract: This invention relates to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy. Specifically, the disclosure provides a CTLA-4 protein comprising a mutant extracellular domain of CTLA-4, wherein the CTLA-4 protein exhibits reduced binding to an anti-CTLA-4 antibody as compared to a wild-type extracellular domain of CTLA-4, wherein the anti-CTLA-4 antibody has anti-cancer immunotherapeutic activity.
    Type: Grant
    Filed: September 19, 2017
    Date of Patent: March 1, 2022
    Assignees: ONCOC4, INC., CHILDREN'S NATIONAL MEDICAL CENTER
    Inventors: Yang Liu, Pan Zheng, Martin Devenport, Wei Wu, Xuexiang Du, Mingyue Liu, Fei Tang
  • Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
    Patent number: 11261251
    Abstract: The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infections diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.
    Type: Grant
    Filed: July 9, 2019
    Date of Patent: March 1, 2022
    Assignees: DANA-FARBER CANCER INSTITUTE, INC., EMORY UNIVERSITY
    Inventors: Gordon J. Freeman, Rafi Ahmed, Timothy D. Jones, Francis J. Carr, James P. Gregson
  • CTLA4-Ig immunoadhesins
    Patent number: 11254727
    Abstract: The present application relates to CTLA4-Ig immunoadhesins that target CD80 and CD86, and their use, particularly for therapeutic purposes.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: February 22, 2022
    Assignee: Xencor, Inc.
    Inventors: Gregory A. Lazar, Matthew J. Bernett
  • Antigen binding proteins that bind PD-1
    Patent number: 11242391
    Abstract: There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: February 8, 2022
    Assignee: SORRENTO THERAPEUTICS, INC.
    Inventors: Heyue Zhou, Barbara A. Swanson, John Dixon Gray, Gunnar F. Kaufmann, Edwige Gros
  • Anti-vista antibodies and fragments
    Patent number: 11242392
    Abstract: The present invention relates to novel antibodies and fragments that bind to a V-domain Ig Suppressor of T cell Activation (VISTA), and methods of making and using same. Methods of use include methods of treatment of cancer, including leukemias, lymphomas, solid tumors and melanomas.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: February 8, 2022
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Linda Snyder, Gordon Powers
  • Cells comprising non-HLA restricted T cell receptors
    Patent number: 11229669
    Abstract: The presently disclosed subject matter provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to novel designs of T cell receptors (TCRs) and engineered immunoresponsive cells comprising the same. The novel TCR binds to an antigen in an HLA-independent manner. In certain embodiments, the novel TCR provides enhanced sensitivity for a target gene having a low expression level.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: January 25, 2022
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Michel Sadelain, Jorge A. Mansilla-Soto, Justin Eyquem, Anton Dobrin
  • Anti-B7-H4 antibodies and immunoconjugates
    Patent number: 11230600
    Abstract: The invention provides anti-B7-H4 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: October 22, 2018
    Date of Patent: January 25, 2022
    Assignee: Genentech, Inc.
    Inventors: Steven R. Leong, Andrew Polson, Paul Polakis, Yan Wu, Wei-Ching Liang, Ron Firestein
  • Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents
    Patent number: 11220545
    Abstract: The present invention relates to methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents.
    Type: Grant
    Filed: December 7, 2015
    Date of Patent: January 11, 2022
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Gordon J. Freeman, Yanping Xiao